Page 468 - TBE_Book_V2_2019
P. 468
Chapter 14: Prevention
82. Dengler TJ, Zimmermann R, Meyer J, Sack FU, 90. Bröker M, Eickmann M, Stadler K. Genetic
Girgsdies O, Kübler WE. Vaccination against tick Stability of a Tick-Borne Encephalitis (TBE)
-borne encephalitis under therapeutic Virus Strain used for the Production of a TBE
immunosuppression. Reduced efficacy in heart Vaccine. J Vaccin Vaccination. 2011;02(01).
transplant recipients. Vaccine. 1999;17:867-74.
91. Xing Yi, Schmitt Heinz-Josef, Arguedas Adriano,
83. Schwarz B. [Health economics of early summer Yang Junfeng. Tick-borne encephalitis in China:
meningoencephalitis in Austria. Effects of a A review of epidemiology and vaccines.
vaccination campaign 1981 to 1990]. Wien Vaccine. 2017;35:1227–1237
Med Wochenschr. 1993;143:551-5.
92. Bröker M, Schöndorf I. Are tick-borne
84. WHO. International Travel and Health, encephalitis vaccines interchangeable? Exp Rev
chapter 6. 2010; available at: http:// Vaccines. 2006;5(4):461-466
www.who.int/ith/ITH2010chapter6.pdf.
93. Litzba N, Zelená H, Kreil TR, Niklasson B,
85. Zavadska D, Anca I, André F, et al. Kühlmann-Rabens I, Remoli ME, Niedrig M.
Recommendations for tick-borne Evaluation of different serological diagnostic
encephalitis vaccination from the Central methods for tick-borne encephalitis virus:
European Vaccination Awareness Group enzyme-linked immunosorbent,
(CEVAG). Hum Vaccin Immunother. immunofluorescence, and neutralization assay.
2013;9:362-74.
Vector Borne Zoonotic Dis. 2014;14(2):149-59.
doi: 10.1089/vbz.2012.1287. Epub 2013 Dec
86. ECDC, European Center for Disease 20.
Prevention and Control. Epidemiological
situation of tick-borne encephalitis in the
European Union and European Free Trade 94. Leonova GN, Pavlenko EV. Characterization of
Association countries. 2012; available at: neutralizing antibodies to far Eastern tick‐
http://ecdc.europa.eu/en/ publications/ borne encephalitis virus subtype and the
Publications/TBE-in-EU-EFTA.pdf. antibody avidity for four tick‐borne
encephalitis vaccines in humans. Vaccine.
2009;27(21):2899‐2904.
87. Konior R, Brzostek J, Poellabauer EM,
Jiang Q, Harper L, Erber W. 95. Maikova GB, Chernokhaeva LL, Rogova YV, et
Seropersistence of TBE virus antibodies al. Ability of inactivated vaccines based on far-
10 years after first booster vaccination eastern tick-borne encephalitis virus strains to
and response to a second booster induce humoral immune response in originally
vaccination with FSME-IMMUN 0.5mL in seropositive and seronegative recipients. J Med
adults. Vaccine. 2017 Jun 16;35(28):3607- Virol. 2019;91(2):190-200.
3613
96. Shedrawy J, Henriksson M, Hergens MP,
Askling HH. Estimating costs and health
88. Beran J, Lattanzi M, Xie F, Moraschini L,
outcomes of publicly funded tick-borne
Galgani I. Second five-year follow-up after
encephalitis vaccination: A cost-effectiveness
a booster vaccination against tick-borne
analysis. Vaccine. 2018;36(50):7659-7665.
encephalitis following different primary
vaccination schedules demonstrates at 97. Bundesamt für Gesundheit (BAG) Bulletin
least 10 years antibody persistence. 6/2019, 4 Feb., 2019
Vaccine. 2018 Feb 1
89. Steffen, NECTM, 2018
463
470
